|
|
|
|
|
|
|
|
|
|
|
08.06.26 - 16:57
|
XETR: Deletion of Instruments from XETRA - 08.06.2026 (XETRA)
|
|
|
The following instruments on XETRA do have their last trading day on 08.06.2026.
Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 08.06.2026.
ISIN Name
US0028962076 Abercrombie & Fitch Co.
US0162551016 Align Technology Inc.
US0311001004 AMETEK Inc.
US1713401024 Church & Dwight Co. Inc.
US1729081059 Cintas Corp.
US22052L1044 Corteva Inc.
US2310211063 Cummins Inc.
US2533931026 Dicks Sporting Goods Inc.
US2910111044 Emerson Electric Co.
US30212P3038 Expedia Group Inc.
FR0004163111 Genfit S.A.
US37940X1028 Global Payments Inc.
US43300A2033 Hilton Worldwide Holdings Inc.
US45168D1046 IDEXX Laboratories Inc.
FR0010331421 Innate Pharma S.A.
US46266C1053 IQVIA Holdings Inc.
US5380341090 Live Nation Entertainment Inc.
US5719032022 Marriott International Inc.
US57667L1070 Match Group Inc.
US5926881054 Mettler-Toledo International Inc.
US5950171042 Microchip Technology Inc.
US6200763075 Motorola Solutions Inc.
US6819191064 Omnicom Group Inc.
US68902V1070 Otis Worldwi...
|
|
|
|
|
25.05.26 - 18:03
|
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026 (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 25, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights its broad participation at EASL Congress 2026. This visibility reflects both its scientific momentum and its active involvement in the ACLF ecosystem, as well as its position at an inflection point in MASH, while also highlighting the continuous progress made in PBC, driven by its partner Ipsen....
|
|
|
|
|
|
|
20.04.26 - 18:03
|
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025) (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 20, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the publication of its 2026 extra-financial performance report (fiscal year 2025), available on its website....
|
|
|
17.04.26 - 17:12
|
XETR: Deletion of Instruments from XETRA - 17.04.2026 -1- (XETRA)
|
|
|
The following instruments on XETRA do have their last trading day on 17.04.2026.
Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026.
ISIN Name
US0028962076 Abercrombie & Fitch Co.
US0162551016 Align Technology Inc.
US02043Q1076 Alnylam Pharmaceuticals Inc.
US0255371017 American Electric Power Co. Inc.
US0311001004 AMETEK Inc.
US0530151036 Automatic Data Processing Inc.
GB00BPQY8M80 Aviva PLC
IE00BD1RP616 Bank of Ireland Group PLC
US14448C1045 Carrier Global Corp.
US8085131055 Charles Schwab Corp.
US16119P1084 Charter Communications Inc. [Del.]
US1713401024 Church & Dwight Co. Inc.
US1255231003 Cigna Group, The
US1729081059 Cintas Corp.
US12572Q1058 CME Group Inc.
US1924461023 Cognizant Technology Solutions Corp.
US2091151041 Consolidated Edison Inc.
US22052L1044 Corteva Inc.
US1264081035 CSX Corp.
US2310211063 Cummins Inc.
US2435371073 Deckers Outdoor Corp.
DK0060738599 Demant AS
US2533931026 Dics Sporting Goods Inc.
US2566771059 Dollar General Co...
|
|
|
07.04.26 - 19:33
|
GENFIT Announces Publication of the 2025 Universal Registration Document (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 07, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2025 Universal Registration Document with the Autorité des marches financiers (AMF; filing n° D.26-0221)....
|
|
|
02.04.26 - 18:33
|
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
|
|
|
Lille, France; Cambridge, MA; Zurich, Switzerland; April 2, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2025 and provided a corporate update. A summary of the consolidated financial statements is included below....
|
|
|
09.03.26 - 18:03
|
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted ODD to NTZ (nitazoxanide), its investigational small-molecule drug candidate developed as a new formulation for the treatment of Acute-on-Chronic Liver Failure (ACLF)....
|
|
|
|
|
|
|
|
|
|
|
07.01.26 - 18:03
|
GENFIT Announces 2026 Financial Calendar (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 7, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2026....
|
|
|
06.01.26 - 18:15
|
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 6, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that G1090N – a small molecule and the Company's lead investigational drug candidate for Acute-On-Chronic Liver Failure (ACLF) – demonstrated a favorable Phase 1 safety profile, and a strong anti-inflammatory activity in ex-vivo studies....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
